AzTrials
AzTrials

Tick BitesTICK REACTNCT07479537

Acquired Tick Resistance in Naturally Exposed Participants

A study testing Tick challenge in people with Tick Bites and Tick Resistance, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Tick-borne diseases are increasing worldwide, and there are currently few effective ways to prevent them. One promising new strategy is to develop a vaccine that targets the tick itself ("anti-tick vaccine") to block the transmission of multiple pathogens. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Tick Bites, Tick Resistance
What is being tested?
Tick challenge
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteNetherlands
Study dates
14 Aug 2025to 1 Jun 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Naturally acquired self-reported tick resistant individuals:
  • Age: 18 - 70 years;
  • History of repeated tick bites
  • Local reaction (like redness or itch) at place of previous tick bites and/or signs of impaired tick feeding after bite (anamnestic)
  • Controls:
  • Age: 18 years - 70 years;
Show all 9Show fewer
  • Experimentally acquired tick resistant individuals:
  • Previous participant in the TICK ME study that has completed all 4 challenges
  • Age: 18 years - 70 years;

Who cannot join

  • Current suspicion of any tick-borne disease
  • Diagnosed with tick-borne disease within the last year
  • Chronic skin condition affecting the skin of the arm;
  • Inability to maintain the dressing for any reason;
  • Known immunodeficiency or autoimmune disease;
  • Use of systemic immunomodulating drugs or chemotherapy, current or in the past;
Show all 22Show fewer
  • Chronic use of antibiotics;
  • Unable to give informed consent or do not have a thorough command of the Dutch language;
  • Refusal to participate in specimen collection and storage for future study related use;
  • Pregnant or breastfeeding women;
  • Not willing to use adequate contraception during the study period;
  • Red meat allergy (both medically confirmed and self-reported);
  • Use of investigational therapy and devices during the time of the study;
  • Any other condition that, in the opinion of the investigator, would make the patient unsuitable for enrolment or could interfere with the patient participating in and completing the study.
  • Additional exclusion criteria for controls:
  • Known history of tick bites;
  • Positive Borrelia serology (VlsE1/PepC10 ELISA);
  • Known history or current suspicion on any tick-borne disease
  • Additional exclusion criteria for experimentally acquired tick resistant individuals:
  • History of tick bites acquired outside of TICK ME study;
  • Positive Borrelia serology (VlsE1/PepC10 ELISA);
  • Known history or current suspicion on any tick-borne disease

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Amsterdam UMC

    Amsterdam, North Holland, 1105AZ

Other trials in Netherlands

About this study

Official title: The Uninfected Ixodes Scapularis Human Tick Challenge Model - Acquired Tick Resistance in Naturally Exposed Participants

Tick-borne diseases are increasing worldwide, and there are currently few effective ways to prevent them. One promising new strategy is to develop a vaccine that targets the tick itself ("anti-tick vaccine") to block the transmission of multiple pathogens. Some animals naturally develop resistance to ticks after repeated tick bites. There are indications that a similar form of acquired tick resistance (ATR) may also occur in humans who have been heavily exposed to ticks. This study investigates whether humans can naturally develop tick resistance and how this affects tick feeding. The investigators will compare people with a long history of tick bites and self-reported signs of tick resistance to people who are tick-naïve. The investigators will also include a small group of volunteers who previously participated in an experimental human tick challenge to evaluate what their reaction on tickbites is 1-2 years after their initial exposures.

Read the detailed description

Study Objectives Primary Objective To determine whether humans develop naturally acquired tick resistance by measuring tick feeding success, specifically the weight of ticks after feeding.

Secondary Objectives To measure additional tick feeding parameters (tick mortality, attachment rate, duration of feeding, and molting).

To assess clinical skin reactions such as itch and redness. To study immune responses (antibodies and immune cells) against tick saliva proteins in all groups.

To identify tick salivary antigens that may be useful for future anti-tick vaccine development.

Study Design Single-center, open-label human experimental tick challenge study.

Three groups:

ATR group: 11 adults with extensive prior tick exposure and self-reported signs of tick resistance.

Control group: 11 adults with no significant tick exposure. Follow-up challenge group: Up to 4 adults previously challenged in the "TICK ME" study.

Outcome measures Primary Outcome Measure Post-feeding tick weight

Secondary Outcome Measures Tick mortality, attachment rate, days attached, and molting success Clinical skin responses (itch, redness) Immune responses to tick salivary proteins Skin biopsy analyses

Being tested
Tick challenge
Keywords
Tick resistance in naturally exposed individuals, tick resistance in tick-naive individuals
Medical subject headings
Tick Bites

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tick challengeOther

    uninfected ixodes scapularis ticks will be placed underneath a closed dressing

Study groups in NCT07479537
Study groupRoleWhat they receive
Tick naive individualsExperimentalIndividuals who have never been bitten by ticks before (as far as known)
Receives: Other: Tick challenge
Supposed tick immune individualsExperimentalIndividuals who have been bitten by a lot of ticks before and experience a local reaction after each tickbite.
Receives: Other: Tick challenge
Previous TICK ME participantsExperimentalIndividuals who have participated in the TICK ME study
Receives: Other: Tick challenge

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Tick feeding: tick weight

    Tick weight measured in mg after complete feeding of the tick

    Measured: From the start of the tick challenge until feeding to repletion of the ticks (max 10 days)

Secondary outcomes (5)
  1. Tick feeding: tick mortality

    Tick mortality in % of fed ticks

    Measured: From the start of the tick challenge until feeding to repletion of the ticks (max 10 days)

  2. Host reaction: redness

    Redness (using a standardized clinical erythema (CEA) score (scale 0-4) which is scored by physicians using photographs of tick bite lesions)

    Measured: Redness will be monitored at day 2 and the last day of the tick challenge

  3. Host reaction: itch

    Itch (using Visual Analogue Scale 0-100) as a sign of a clinical reaction of the host

    Measured: Itch is measures daily during the tick challenge (From the start of the tick challenge until feeding to repletion of the ticks (max 10 days)

  4. Host immune response: humoral

    Humoral (qualitative by characterizing antibodies recognizing anti-tick antigens using a yeast surface display expressing tick salivary gland proteins)

    Measured: From the start of the challenge, day 2, day 5, final day of challenge (day 5-10) depending upon tick feeding, 3-5 weeks after the challenge and 10-12 weeks after the challenge

  5. Host immune response: cellular

    Cellular (immunophenotyping of the different immune subsets in collected PBMCs at the specified time points) of immune responses in blood

    Measured: From the start of the challenge, day 2, day 5, final day of challenge (day 5-10) depending upon tick feeding, 3-5 weeks after the challenge and 10-12 weeks after the challenge

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Mar 2026
  2. Study start14 Aug 2025
  3. Primary completion1 Apr 2026
  4. Study completion1 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07479537
Sponsor's protocol ID
NL-009527
Acronym
TICK REACT
Status last verified
Jun 2026
First submitted
3 Dec 2025
Last updated
10 Jun 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: The descision about sharing the IPD will follow

Questions about this trial

What is this clinical trial studying?

A study testing Tick challenge in people with Tick Bites and Tick Resistance, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Tick feeding: tick weight (time frame: From the start of the tick challenge until feeding to repletion of the ticks (max 10 days)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in